ClinicaliQ Trial Snapshot
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed — Recruiting • Phase I • Oncology • NCT06885034.
- What is being tested: GSK5764227, a novel therapeutic agent, is being evaluated for safety, efficacy, and pharmacokinetics as monotherapy or in combination with other treatments in patients with advanced gastrointestinal cancers.
- Patient eligibility overview: The trial includes adults with advanced, inoperable or metastatic gastrointestinal cancers who have received prior treatment and are enrolled across multiple international centres.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Eligibility Snapshot
- : Participants are eligible to be included in the study only if all of the following criteria apply: • Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable/, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). * Must have received at least 1 and no more than 2 lines of systemic treatment for advanced colorectal cancer (CRC), with documented progression on most recent prior line of therapy. * Must provide tumor tissue from a newly obtained fresh biopsy or an archival tumor tissue. PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification). * Must have received 1 and no more than 1 line of therapy for advanced PDAC, with documented progression. * Should provide tumor tissue at screening, where available or medically feasible. All Cohorts * Has at least 1 target lesion per RECIST 1.1, as determined by the investigator. * Is willing to…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.